February 2, 2006 – Cephalon settled the last of its patent disputes surrounding Provigil, this time coming to terms with Barr Pharma; Cephalon also said the FDA will take an additional 3 months before ruling on Nuvigil; Genta presented positive Phase III data on its cancer drug Genasense; Valera became a public company today, selling 3.75 million shares at $9 in its IPO; also this week, Iomai priced at $7, the low end of its reduced range, and SGX Pharma priced at $6, down from an $11 to $13 range; Schering Plough won FDA approval for a 12-hour extended release version of Clarinex; the FDA gave its OK to GlaxoSmithKline for an injected version of migraine drug Imitrex; ISTA Pharma reported positive data on a combination drug for eye inflammation; CytRx pointed to a journal article supporting the mechanims of its diabetes drug candidate; and Nabi said Civacir, a hepatitis C immune globulin, received fast track status. The Centient Biotech 200™ was off by 34 points at 3951.69, a loss of .85%. More details...
